6533b837fe1ef96bd12a2989
RESEARCH PRODUCT
Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases?
Alberto PapiFulvio BraidoPierachille SantusAlida BenfanteMarialuisa BocchinoScichilone NicolaPierluigi PaggiaroAlessandro Sanduzzisubject
Pulmonary and Respiratory Medicinemedicine.medical_specialtyChronic ObstructiveSocio-culturaleSettore MED/10 - Malattie Dell'Apparato RespiratorioAffect (psychology)Anti-asthmatic AgentMedication AdherencePulmonary DiseasePulmonary Disease Chronic ObstructiveSuspensionsAdministration InhalationmedicineCOPDHumansPharmacology (medical)Anti-Asthmatic AgentsMetered Dose InhalersRespiratory systemParticle SizeIntensive care medicineAsthmaAdherence; Asthma; COPD; Inhaler; Administration Inhalation; Anti-Asthmatic Agents; Dry Powder Inhalers; Humans; Medication Adherence; Metered Dose Inhalers; Particle Size; Pulmonary Disease Chronic Obstructive; Solutions; Suspensions; Nebulizers and Vaporizers; Pulmonary and Respiratory Medicine; Pharmacology (medical); Biochemistry (medical); Medicine (all)COPDInhalationbusiness.industryMedicine (all)InhalerNebulizers and VaporizersBiochemistry (medical)Adherence; Asthma; COPD; Inhaler; Administration Inhalation; Anti-Asthmatic Agents; Dry Powder Inhalers; Humans; Medication Adherence; Metered Dose Inhalers; Particle Size; Pulmonary Disease Chronic Obstructive; Solutions; Suspensions; Nebulizers and Vaporizers; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)InhalerDry Powder InhalersAirway obstructionmedicine.diseaseAsthmaSolutionsInhalationAdherenceAdministrationAdherence; Asthma; COPD; Inhalerbusinessdescription
Inhalation is the preferred route of drug administration in chronic respiratory diseases because it optimises delivery of the active compounds to the targeted site and minimises side effects from systemic distribution. The choice of a device should be made after careful evaluation of the patient's clinical condition (degree of airway obstruction, comorbidities), as well as their ability to coordinate the inhalation manoeuvre and to generate sufficient inspiratory flow. These patient factors must be aligned with the specific advantages and limitations of each inhaler when making this important choice. Finally, adherence to treatment is not the responsibility of the patient alone, but should be shared also by clinicians. Clinicians have access to a wide selection of pressurised metered dose inhalers (pMDIs) and dry powder inhalers (DPIs) that can be used effectively when matched to the needs of individual patients; this should be perceived as an opportunity rather than a limitation.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2015-04-01 | Pulmonary pharmacologytherapeutics |